Natalie Trevaskis

Dr Natalie Trevaskis profile

Dr Natalie Trevaskis

Drug Delivery, Disposition and Dynamics
Monash Institute of Pharmaceutical Sciences

Phone: + 61 3 990 39708


ROPES profile

Google Scholar

Every day I wake up and think that today might be the day that my group or another group of scientists at MIPS discovers something that substantially advances human health. What could be more exciting than being a part of that?

Dr Trevaskis is developing novel chaperones to direct drugs to sites of action. The chaperones maximize drug efficacy and minimize harmful side effects due to uncontrolled drug disposition to off-target sites. Using these chaperones she aims to provide solutions for diseases promoted by obesity such  as  heart disease, diabetes, immune disease and cancer. The lymphatic system plays a major role in these diseases, as such chaperones to direct drugs to the lymphatics are a core focus. Outside the lab Dr Trevaskis loves to play with her two young sons and has a passion for long distance running.

Recent media items

Harnessing lipid absorption pathways to target the lymphatic system

Recent advances in lipid-based formulation technology

Selected recent publications

Han S, Quach T, Hu L, Wahab A, Charman WN, Stella VI, Trevaskis NL, Simpson JS, Porter CJH. Targeted delivery of a model immunomodulator to the lymphatic system: Comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies J Control. Rel. 2014;177:1-10.

Yeap YY, Trevaskis NL, Porter CJH. Lipid Absorption Triggers Drug Supersaturation at the Intestinal Unstirred Water Layer and Promotes Drug Absorption from Mixed Micelles. Pharm Res. 2013;30:3045-58.

Caliph SC, Cao E, Hu L, Han S, Porter CJH, Trevaskis NL. The impact of lymphatic transport on the systemic disposition of lipophilic drugs. J Pharm Sci. 2013; 102(7):2395-408.

Trevaskis NL, Caliph SM, Nguyen G, Tso P, Charman WN, Porter CJH.  A Mouse Model to Evaluate the Impact of Species, Sex and Lipid Load on Lymphatic Drug Transport.  Pharm. Res. 2013;30 (12):3254-70.

Williams HD, Trevaskis NL, Charman SA, Shanker RM, Charman WN, Pouton CW, Porter CJH.  Strategies to Address Low Drug Solubility in Discovery and Development. Pharmacological reviews. 2013;65(1):315-499.

Trevaskis NL, Charman WN, Porter CJH. Targeted drug delivery to lymphocytes: a route to site-specific immunomodulation. Mol Pharmaceutics. 2010;7:2297-2309.

Trevaskis NL, McEvoy CL, McIntosh MP, Shanker RM, Charman WN, Porter CJH. The role of the intestinal lymphatics in the absorption of two highly lipophilic cholesterol ester transfer protein inhibitors (CP524,515 and CP532,623). Pharm. Res. 2010;27:878-893.

Trevaskis NL, Shackleford DM, Charman WN, Edwards GA, Gardin A, Appel-Dingemanse S, Kretz O, Galli B, Porter CJH. Intestinal lymphatic transport enhances the post prandial oral bioavailability of a novel cannabinoid receptor agonist via avoidance of first pass metabolism. Pharm. Res. 2009;26:1486-495.

Trevaskis NL, Charman WN, Porter CJH.  Lipid based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv. Drug Deliv. Rev. 2008;60:702-716.

Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimising the oral delivery of lipophilic drugs. Nat. Rev. Drug Discov. 2007;6:231-248.